2026
Barry-Simonnet C, Crouzier L, Moujellil-Legagneur T, Chaieb-Errass H, Idres YA, Ferrare K, Rolland M, Cazals G, Poucheret P, Maurice T, Tousch D. Xanthatin-13-(Pyrrolidine-2-Carboxylic Acid), a Sesquiterpene Lactone Isolated From Burdock Leaf, Attenuated Aβ25-35 Toxicity and Memory Deficits in a Pharmacological Mouse Model of Alzheimer’s Disease. Phytother Res. March 7, 2026. doi: 10.1002/ptr.70294.
Blanch R, Esandi J, Guerrero-Yagüe R, del Rey J, Roig-Soriano J, Lleo A, Carro E, Mestre-Francés N, Devau G, Ferrer I, Meseguer A, Lanciego JL, Almolda B, Bosch B, Chillón M. The sKL/mKL Transcript Ratio and Protein Localization Define a Species- and Region-Specific Klotho Signature in the CNS and AD Progression. Genes and Diseases 2026 (in press)
Coste J, Carcaillon-Bentata L, Robine JM, Trouvin AP, Humphreys J, Guillemin F. Trends in the prevalence and disability burden of major rheumatic and musculoskeletal diseases in France, 2008–2022. RMD Open. May 11, 2026;12(2):e006584. doi: 10.1136/rmdopen-2025-006584.
Grasso M, Moser PO, Sauvageot S, Gil V, Chan-Seng E, Sanrey E, Coubes P, Poulen G. Putamen Atrophy as a Predictive Factor of the Efficacy of GPi-DBS in Dystonia-Dyskinesia Syndrome Secondary to Perinatal Anoxic Encephalopathy. Mov Disord. March 18, 2026. doi: 10.1002/mds.70275.
Grasso M, Coelho C, Chan-Seng E, Coubes P, Poulen G. Perinatal Post-Anoxic Spinal Cord Injury: A Barrier to Pallidal Neuromodulation? A Report on 2 Cases. Mov Disord Clin Pract. March 20, 2026. doi: 10.1002/mdc3.70602.
Gazard CM, Poulen G, Perrin FE. Glial heterogeneity in the primate spinal cord: Implications of age and sex differences for neurodegenerative and neurotraumatic diseases. Neural Regen Res. Jan. 27, 2026. doi: 10.4103/NRR.NRR-D-25-01274.
Hersent C, Larrieu L, Fergelot P, Miro J, Benkirane M, Angelini C, Ramond F, Marelli C, Sabatier I, Lesca G, Vaché C, Cossée M, Bergougnoux A, Dieterich K, Tranchant C, Marey I, Castrioto A, Thauvin-Robinet C, Abou Haidar L, Rivier F, Tuffery-Giraud S, Koenig M. Decoding splicing variants in high-throughput sequencing: a functional validation approach integrating deep learning tools. Eur J Hum Genet. 2026 Aug;34(8):1165-1175. doi: 10.1038/s41431-026-02162-2.
Marelli C, Charret Q, Goizet C, Thevenon J, Bernard V, Ory Magne F, Degoutin M, Fergelot P, Renaud M, Koenig M, Ramond F. STUB1 (SCA48)/TBP (SCA17): A Frequent Association Still Not Fully Explained and a Lower Threshold for Intermediate Expanded TBP Alleles. Mov Disord. 2026 Jul;41(7):1661-1665. doi: 10.1002/mds.70296.
Mastropasqua F, Lisi AT, Crouzier L, Musillo GR, Abatematteo FS, Niso M, Delprat B, Colabufo NA, Nanna V, Mangiatordi GF, Delre P, Spalholz T, Colella M, Deuther-Conrad W, Loiodice F, Maurice T, Laghezza A, Abate C. Development of Second-Generation Phenoxyethylpiperidines as Potent Sigma-1 Receptor Agonists with Neuroprotective Potential for Alzheimer’s Disease. J Med Chem. Feb 26, 2026;69(4):4613-4628. doi: 10.1021/acs.jmedchem.5c03240.
Maurice T. σ1 receptor agonists: the new trend or an emerging therapeutic option? Expert Opin Emerg Drugs. 2026 Jul 2:1-4. doi: 10.1080/14728214.2026.2696872. .
Menéndez Soto del Valle R, Barry-Simonnet C, Verjus L, Crouzier L, Peña Alcolea S, Sablón Carrazana M, Maurice T, Rodríguez-Tanty C. Enhanced cognitive protection through the combination of Amylovis-201, an anti-amyloidogenic agent with sigma-1 receptor agonist activity, and environmental enrichment in mice. J Psychopharmacol. 2026, in press.
Otaegui L, Lehoux J, Begu S, Moujellil-Legagneur T, Zussy C, Vitalis M, Mathias M, Beau A, Durand T, Givalois L, Bernoud-Hubac N, Crauste C, Desrumaux C. Intranasal lipid nanocapsule administration of the new lipophenol quercetin-3-O-DHA-7-O-iPr reduces carbonyl stress and improves behavior in a mouse model of Alzheimer’s disease. Drug Deliv Transl Res. 2026 May 6. doi: 10.1007/s13346-026-02142-5.
Reichau K, Crouzier L, Poeta E, Gehrig T, Schaller E, Zvejniece L, Meunier J, Sotriffer C, Monti B, Maurice T, Decker M. A Dual Approach to Combat Alzheimer’s Disease through Concomitant hBChE Inhibition and S1R Activation. ACS Chem Neurosci. Feb 18, 2026;17(4):805-822. doi: 10.1021/acschemneuro.5c00921.
Reichau K, Crouzier L, Gehrig T, Flake A, Schaller E, Meunier J, Bertrand-Gaday C, Chatonnet A, Zvejniece L, Sotriffer C, Maurice T, Decker M. Targeting neuroinflammation by activating the sigma-1 receptor (S1R) and inhibiting butyrylcholinesterase (hBChE) leads to highly potent anti-amnesic compounds in a mouse model of Alzheimer’s disease. Eur J Med Chem. March 5, 2026;305:118486. doi: 10.1016/j.ejmech.2025.118486.
Sałaciak K, Lustyk K, Jagielska A, Szafarz M, Inteiro-Oliveira S, Diógenes MJ, Xapelli S, Schnur P, Morton L, Moran E, Ferreira J, Sakata S, Crouzier L, Meunier J, Delprat B, Maurice T, Pytka K. The multimodal Sigma-1-targeting compound HBK-15 reverses memory deficits and restores hippocampal plasticity in the presence of NMDA hypofunction. Neurotherapeutics. Jan 2026;23(1):e00774. doi: 10.1016/j.neurot.2025.e00774.
Travers-Lesage V, Crouzier L, Antonijevic M, Wang A, Toublet FX, Davis A, Modeste F, Brazzolotto X, Nachon F, Since M, Maurice T, Rochais C, Dallemagne P. Access to novel, potent, pleiotropic prodrugs that target both butyrylcholinesterase and serotonin reuptake and exhibit anti-amnesic activity in an Alzheimer’s disease model. Eur J Med Chem. April 5, 2026;307:118670. doi: 10.1016/j.ejmech.2026.118670.
Travers–Lesage V, Since M, Wang A, Davis A, Fayolle D, Bernay B, Modeste F, Nachon F, Brazzolotto X, Crouzier L, Sopkova-De Oliveira Santos J, Maurice T, Dallemagne P, Rochais C. Rational design and evaluation of rivastigmine-based pleiotropic prodrugs for the treatment of Alzheimer’s disease. ACS Chem Neurosci. April 13, 2026. doi: 10.1021/acschemneuro.6c00170